Upregulated expression of AT‑rich interactive domain‑containing protein 1B predicts poor prognosis in patients with triple‑negative breast cancer

Cui,Yan; Bai,Xianan; Niu,Ming; Qin,Yu; Zhang,Xianyu; Pang,Da

doi:10.3892/ol.2019.9961

Upregulated expression of AT‑rich interactive domain‑containing protein 1B predicts poor prognosis in patients with triple‑negative breast cancer

Authors:
- Yan Cui
- Xianan Bai
- Ming Niu
- Yu Qin
- Xianyu Zhang
- Da Pang
View Affiliations

Affiliations: Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China, Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China
Published online on: January 23, 2019 https://doi.org/10.3892/ol.2019.9961
Pages: 3289-3295
Copyright: © Cui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression of AT‑rich interactive domain‑containing protein 1B (ARID1B) was investigated in triple‑negative breast cancer (TNBC). The association between ARID1B protein expression and the prognosis of patients with TNBC was investigated. The expression of ARID1B was examined in TNBC (n=142) and adjacent normal breast tissues (n=64) using immunohistochemical staining prior to the patients receiving any treatment. Furthermore, the association between ARID1B protein expression and various clinicopathological features was analyzed, including the survival status of patients with TNBC. Of the 142 TNBC tissues, ARID1B was highly expressed in 89 (62.7%) and poorly expressed in 53 (37.3%). ARID1B expression was associated with lymph node metastasis status, histological grade and p53 expression. ARID1B expression was upregulated significantly in the nuclei of TNBC cells compared with those of normal mammary epithelial cells. This upregulation was associated with a decreased progression‑free survival rate (P=0.002) and overall survival rate (P=0.003). The results of the present study indicate that significant association exists between the nuclear expression of ARID1B and adverse prognosis in TNBC. Therefore, ARID1B may be a useful prognostic biomarker in TNBC.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
3	Yang Q, Liu HY, Liu D and Song YQ: Ultrasonographic features of triple-negative breast cancer: A comparison with other breast cancer subtypes. Asian Pac J Cancer Prev. 16:3229–3232. 2015. View Article : Google Scholar : PubMed/NCBI
4	Reisman D, Glaros S and Thompson EA: The SWI/SNF complex and cancer. Oncogene. 28:1653–1668. 2009. View Article : Google Scholar : PubMed/NCBI
5	Phelan ML, Sif S, Narlikar GJ and Kingston RE: Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. Mol Cell. 3:247–253. 1999. View Article : Google Scholar : PubMed/NCBI
6	Inoue H, Furukawa T, Giannakopoulos S, Zhou S, King DS and Tanese N: Largest subunits of the human SWI/SNF chromatin-remodeling complex promote transcriptional activation by steroid hormone receptors. J Biol Chem. 277:41674–41685. 2002. View Article : Google Scholar : PubMed/NCBI
7	Nagl NG Jr, Wang X, Patsialou A, Van Scoy M and Moran E: Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. EMBO J. 26:752–763. 2007. View Article : Google Scholar : PubMed/NCBI
8	Hoyer J, Ekici AB, Endele S, Popp B, Zweier C, Wiesener A, Wohlleber E, Dufke A, Rossier E, Petsch C, et al: Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of intellectual disability. Am J Hum Genet. 90:565–572. 2012. View Article : Google Scholar : PubMed/NCBI
9	Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, Blackford A, Parmigiani G, Diaz LA Jr, Papadopoulos N, et al: Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet. 45:12–17. 2013. View Article : Google Scholar : PubMed/NCBI
10	Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, et al: The landscape of cancer genes and mutational processes in breast cancer. Nature. 486:400–404. 2012. View Article : Google Scholar : PubMed/NCBI
11	Shao F, Guo T, Chua PJ, Tang L, Thike AA, Tan PH, Bay BH and Baeg GH: Clinicopathological significance of ARID1B in breast invasive ductal carcinoma. Histopathology. 67:709–718. 2015. View Article : Google Scholar : PubMed/NCBI
12	Khursheed M, Kolla JN, Kotapalli V, Gupta N, Gowrishankar S, Uppin SG, Sastry RA, Koganti S, Sundaram C, Pollack JR and Bashyam MD: ARID1B, a member of the human SWI/SNF chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines. Br J Cancer. 108:2056–2062. 2013. View Article : Google Scholar : PubMed/NCBI
13	Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, Cleeland C, Dotan E, Eisenberger MA, Escalante CP, et al: Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw. 13:1012–1039. 2015. View Article : Google Scholar : PubMed/NCBI
14	Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
15	Kobayashi T, Iwaya K, Moriya T, Yamasaki T, Tsuda H, Yamamoto J and Matsubara O: A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer. BMC Clin Pathol. 13:52013. View Article : Google Scholar : PubMed/NCBI
16	Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
17	Asleh-Aburaya K and Fried G: Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: Single center experience. Springerplus. 4:1322015. View Article : Google Scholar : PubMed/NCBI
18	Weissman B and Knudsen KE: Hijacking the chromatin remodeling machinery: Impact of SWI/SNF perturbations in cancer. Cancer Res. 69:8223–8230. 2009. View Article : Google Scholar : PubMed/NCBI
19	Wilson BG and Roberts CW: SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 11:481–492. 2011. View Article : Google Scholar : PubMed/NCBI
20	Wang X, Nagl NG, Wilsker D, Van Scoy M, Pacchione S, Yaciuk P, Dallas PB and Moran E: Two related ARID family proteins are alternative subunits of human SWI/SNF complexes. Biochem J. 383:319–325. 2004. View Article : Google Scholar : PubMed/NCBI
21	Zhao J, Liu C and Zhao Z: ARID1A: A potential prognostic factor for breast cancer. Tumour Biol. 35:4813–4819. 2014. View Article : Google Scholar : PubMed/NCBI
22	Mamo A, Cavallone L, Tuzmen S, Chabot C, Ferrario C, Hassan S, Edgren H, Kallioniemi O, Aleynikova O, Przybytkowski E, et al: An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene. 31:2090–2100. 2012. View Article : Google Scholar : PubMed/NCBI
23	Guan B, Gao M, Wu CH, Wang TL and Shih Ie M: Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. Neoplasia. 14:986–993. 2012. View Article : Google Scholar : PubMed/NCBI
24	Wu JN and Roberts CW: ARID1A mutations in cancer: Another epigenetic tumor suppressor? Cancer Discov. 3:35–43. 2013. View Article : Google Scholar : PubMed/NCBI
25	Flores-Alcantar A, Gonzalez-Sandoval A, Escalante-Alcalde D and Lomeli H: Dynamics of expression of ARID1A and ARID1B subunits in mouse embryos and in cells during the cell cycle. Cell Tissue Res. 345:137–148. 2011. View Article : Google Scholar : PubMed/NCBI
26	Sim JC, White SM, Fitzpatrick E, Wilson GR, Gillies G, Pope K, Mountford HS, Torring PM, McKee S, Vulto-van Silfhout AT, et al: Expanding the phenotypic spectrum of ARID1B-mediated disorders and identification of altered cell-cycle dynamics due to ARID1B haploinsufficiency. Orphanet J Rare Dis. 9:432014. View Article : Google Scholar : PubMed/NCBI
27	Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K and Levy DE: New and old functions of STAT3: A pivotal target for individualized treatment of cancer. Cell Cycle. 4:1131–1133. 2005. View Article : Google Scholar : PubMed/NCBI
28	Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ, et al: ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med. 20:251–254. 2014. View Article : Google Scholar : PubMed/NCBI